Section Arrow
BLRX.NASDAQ
- BioLineRx Ltd
Quotes are at least 15-min delayed:2025/07/17 07:44 EDT
Pre Market
Last
 4.51
-0.09 (-1.96%)
Bid
4.46
Ask
4.59
High 4.6 
Low 4.51 
Volume 82 
Regular Hours
Last
 4.6
+0.08 (+1.77%)
Day High 
4.6982 
Prev. Close
4.52 
1-M High
5.0632 
Volume 
19.08K 
Bid
4.46
Ask
4.59
Day Low
4.4702 
Open
4.6982 
1-M Low
3.79 
Market Cap 
16.82M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.6 
20-SMA 4.51 
50-SMA 4.22 
52-W High 35.6 
52-W Low 2.3001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.00/-20.49
Enterprise Value
26.86M
Balance Sheet
Book Value Per Share
5.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
Pre Market 1.77 -0.17 -8.76%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
Pre Market 0.102 -0.007 -6.42%
NCNANuCana plc0.0502--0.000%-- 
Pre Market 0.0485 -0.0017 -3.39%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
Pre Market 1.36 -0.06 -4.23%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
Pre Market 1.3 +0.4 +44.44%
Quotes are at least 15-min delayed:2025/07/17 07:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.